Thursday March 9th @ 4 pm CET (10 am EST)
Don’t miss our upcoming webinar on stem cell-based pain and CNS drug discovery. Attendees can gain knowledge of compound profiling to advance research in the CNS and pain therapeutic fields and get an understanding of the principles of operation of Cellectricon’s phenotypic screening platform.
Paul Karila, VP of Discovery Services, Cellectricon
Ashley Barnes, Head of Drug Discovery Services, Censo Biotechnologies
Cellectricon and Censo Biotechnologies introduce a joint technology access program utilizing high-quality Human iPSC-based discovery services for CNS and pain research
Mölndal, Sweden and Cambridge, UK – 26th January 2017
Cellectricon AB and Censo Biotechnologies Ltd are announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research.Read more
Cellectricon and Censo Biotechnologies collaborate to offer high-quality Human iPSC-based discovery services for CNS and pain research
Mölndal, Sweden and Cambridge, UK – 8th September 2016
Cellectricon AB, a leading provider of advanced cell-based discovery screening services, today announced a commercial collaboration with UK-based stem cell technology company Censo Biotechnologies Ltd. Under the agreement, the parties will provide a suite of high-quality Human iPSC based discovery services to support both preclinical neuroscience and chronic pain research.Read more
Mölndal, Sweden, 7 June 2016
Cellectricon AB, a leading provider of advanced cell-based Discovery Services, today announced a commercial collaboration with UK-based research company Neurexpert Ltd. Under the agreement, Cellectricon and Neurexpert will co-promote their combined CNS drug discovery expertise, with a particular focus on synaptic function assays, for research into treatments of central nervous system disorders in the fields of psychiatry, neurology, pain and neurodegeneration.Read more
You can now download our latest whitepaper – A novel phenotypic screening platform targeting chronic pain drug discovery
Chronic pain is a disease area with a significant and unmet need for improved treatments. However, due to the complex nature of pain transduction, pain is a notoriously difficult area for drug discovery, where conventional target-based efforts have largely failed to produce new drugs.
In this whitepaper, we present a novel phenotypic screening cascade based on our proprietary Cellaxess® Elektra technology. This cascade provides an exciting opportunity to efficiently identify new classes of compounds that affect neuronal excitability in primary peripheral pain-sensing neurons, while sparing the CNS and cardiovascular system. Important decisions about which compounds to advance to further testing and which to eliminate can be made in a seamless operation much earlier along the discovery process.Read more
- Page 1 of 14